Pharmacological and emerging therapies in the treatment of chronic angina

The Lancet

Volumn 386, Issue 9994, 2015, Pages 691-701

  Husted, Steen E ^a,b   Ohman, E Magnus ^c  

^a REGIONAL HOSPITAL WEST JUTLAND   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIANGINA PECTORIS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; IVABRADINE; NICORANDIL; NITRIC ACID DERIVATIVE; PERHEXILINE MALEATE; RANOLAZINE; RHO KINASE INHIBITOR; TRIMETAZIDINE; CARDIOVASCULAR AGENT;

ANGINA PECTORIS; ARTICLE; ATRIOVENTRICULAR CONDUCTION; BLOOD VESSEL TONE; CHELATION THERAPY; CHRONIC ANGINA; CHRONIC DISEASE; CLOSED ANGLE GLAUCOMA; CORONARY ARTERY DILATATION; DENITRIFICATION; DISEASE COURSE; GENE THERAPY; HEART MUSCLE CONTRACTILITY; HEART MUSCLE OXYGEN CONSUMPTION; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HUMAN; JUXTAGLOMERULAR CELL; META ANALYSIS (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STEM CELL TRANSPLANTATION; SYMPATHETIC TONE; PHARMACEUTICS;

ADRENERGIC BETA-ANTAGONISTS; ANGINA PECTORIS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR AGENTS; CHRONIC DISEASE; HUMANS; NITRATES; TECHNOLOGY, PHARMACEUTICAL;

EID: 84939437348     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)61283-1     Document Type: Review

References (86)

1. G Montalescot, U Sechtem, S Achenbach the Task Force Members 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology Eur Heart J 34 2013 2949 3003
2. R Kones Recent advances in the management of chronic stable angina I: approach to the patient, diagnosis, pathophysiology, risk stratification, and gender disparities Vasc Health Risk Manag 6 2010 635 656
3. ST O'Rourke Nitro vasodilators: pharmacology and use in the treatment of myocardial ischemia Am J Pharm Educ 66 2002 177 180
4. JD Parker, JO Parker Nitrate therapy for stable angina pectoris N Engl J Med 338 1998 520 531
5. M Bøttcher, MM Madsen, F Randsbaek et al. Effect of oral nitroglycerin and cold stress on myocardial perfusion in areas subtended by stenosed and nonstenosed coronary arteries Am J Cardiol 89 2002 1019 1024
6. RJ Gibbons, J Abrams, K Chatterjee the American College of Cardiology the American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina) ACC/AHA 2002 guideline update for the management of patients with chronic stable angina - summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina) J Am Coll Cardiol 41 2003 159 168
7. PA Heidenreich, KM McDonald, T Hastie et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina JAMA 281 1999 1927 1936
8. JO Parker, B Farrell, KA Lahey, G Moe Effect of intervals between doses on the development of tolerance to isosorbide dinitrate N Engl J Med 316 1987 1440 1444
9. SD Fihn, JM Gardin, J Abrams the American College of Cardiology Foundation the American Heart Association Task Force on Practice Guidelines the American College of Physicians the American Association for Thoracic Surgery the Preventive Cardiovascular Nurses Association the Society for Cardiovascular Angiography and Interventions the Society of Thoracic Surgeons 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease J Am Coll Cardiol 60 2012 e44 164
10. C Dessy, JL Balligand Beta3-adrenergic receptors in cardiac and vascular tissues emerging concepts and therapeutic perspectives Adv Pharmacol 59 2010 135 163
11. SS Gottlieb, RJ McCarter, RA Vogel Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction N Engl J Med 339 1998 489 497
12. D Tepper Frontiers in congestive heart failure: Effect of Metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Congest Heart Fail 5 1999 184 185
13. SJ Kernis, KJ Harjai, GW Stone et al. Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? J Am Coll Cardiol 43 2004 1773 1779
14. PM Short, SI Lipworth, DH Elder, S Schembri, BJ Lipworth Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study BMJ 342 2011 d2549
15. BM Psaty, TD Koepsell, EH Wagner, JP LoGerfo, TS Inui The relative risk of incident coronary heart disease associated with recently stopping the use of β-blockers JAMA 263 1990 1653 1657
16. MH Alderman, H Cohen, R Roqué, S Madhavan Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients Lancet 349 1997 594 598
17. PA Poole-Wilson, J Lubsen, BA Kirwan on behalf of the ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system) investigators Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial Lancet 364 2004 849 857
18. WH Frishman, DA Sica Calcium channel blockers WH Frishman EH Sonnenblick DA Sica Cardiovascular Pharmacotherapeutics 2003 McGraw-Hill New York
19. DR Abernethy, JB Schwartz Calcium-antagonist drugs N Engl J Med 341 1999 1447 1457
20. MD Ezekowitz, K Hossack, JL Mehta et al. Amlodipine in chronic stable angina: results of a multicenter double-blind crossover trial Am Heart J 129 1995 527 535
21. K Boman, H Saetre, LG Karlsson et al. Antianginal effect of conventional and controlled release diltiazem in stable angina pectoris Eur J Clin Pharmacol 49 1995 27 30
22. RN Brogden, P Benfield Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease Drugs 51 1996 792 819
23. CJ Pepine, RL Feldman, J Whittle, RC Curry, CR Conti Effect of diltiazem in patients with variant angina: a randomized double-blind trial Am Heart J 101 1981 719 725
24. The Multicenter Diltiazem Postinfarction Trial Research Group The effect of diltiazem on mortality and reinfarction after myocardial infarction N Engl J Med 319 1988 385 392
25. JC Tardif, P Ponikowski, T Kahan the ASSOCIATE Study Investigators Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II - DAVIT II) Am J Cardiol 66 1990 779 785
26. EM Jolicoeur, EM Ohman, R Temple the Working Group Members Clinical and research issues regarding chronic advanced coronary artery disease part II: Trial design, outcomes, and regulatory issues Am Heart J 155 2008 435 444
27. AK Gupta, D Winchester, CJ Pepine Antagonist molecules in the treatment of angina Expert Opin Pharmacother 14 2013 2323 2342
28. R Joannides, N Moore, M Iacob et al. Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise Br J Clin Pharmacol 61 2006 127 137
29. JS Borer, K Fox, P Jaillon, G Lerebours the Ivabradine Investigators Group Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial Circulation 107 2003 817 823
30. JC Tardif, I Ford, M Tendera, MG Bourassa, K Fox the INITIATIVE Investigators Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina Eur Heart J 26 2005 2529 2536
31. W Ruzyllo, M Tendera, I Ford, KM Fox Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial Drugs 67 2007 393 405
32. JC Tardif, P Ponikowski, T Kahan the ASSOCIATE study investigators Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial Eur Heart J 30 2009 540 548
33. N Hayata, H Araki, M Nakamura Effects of nicorandil on exercise tolerance in patients with stable effort angina: a double-blind study Am Heart J 112 1986 1245 1250
34. TB Meany, P Richardson, AJ Camm et al. Exercise capacity after single and twice-daily doses of nicorandil in chronic stable angina pectoris Am J Cardiol 63 1989 66J 70J
35. S Di Somma, V Liguori, M Petitto et al. A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris Cardiovasc Drugs Ther 7 1993 119 123
36. G Döring Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients J Cardiovasc Pharmacol 20 suppl 3 1992 S74 S81
37. R Rajaratnam, DB Brieger, R Hawkins, SB Freedman Attenuation of anti-ischemic efficacy during chronic therapy with nicorandil in patients with stable angina pectoris Am J Cardiol 83 1999 1120 1124 A9.
38. M Schartl, C Dougherty, W Rutsch, H Schmutzler Hemodynamic effects of molsidomine, isosorbide dinitrate, and nifedipine at rest and during exercise Am Heart J 109 1985 649 653
39. F Wagner, C Gohlke-Barwolf, D Trenk, E Jahnchen, H Roskamm Differences in the antiischaemic effects of molsidomine and isosorbide dinitrate (ISDN) during acute and short-term administration in stable angina pectoris Eur Heart J 12 1991 994 999
40. R Messin, G Boxho, J De Smedt, IM Buntinx Acute and chronic effect of molsidomine extended release on exercise capacity in patients with stable angina, a double-blind cross-over clinical trial versus placebo J Cardiovasc Pharmacol 25 1995 558 563
41. R Messin, G Opolski, T Fenyvesi et al. Efficacy and safety of molsidomine once-a-day in patients with stable angina pectoris Int J Cardiol 98 2005 79 89
42. K Werdan, H Ebelt, S Nuding, F Höpfner, G Hack, U Müller-Werdan Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study Clin Res Cardiol 101 2012 365 373
43. K Fox, I Ford, PG Steg, JC Tardif, M Tendera, R Ferrari the SIGNIFY Investigators Ivabradine in stable coronary artery disease without clinical heart failure N Engl J Med 371 2014 1091 1099
44. EM Ohman, KP Alexander The challenges with chronic angina N Engl J Med 371 2014 1152 1153
45. K Fox, I Ford, PG Steg, M Tendera, R Ferrari on behalf of the BEAUTIFUL Investigators Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial Lancet 372 2008 807 816
46. H Suryapranata, PW Serruys, PJ De Feyter, PD Verdouw, PG Hugenholtz Coronary vasodilatory action after a single dose of nicorandil Am J Cardiol 61 1988 292 297
47. The IONA Study Group Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial Lancet 359 2002 1269 1275
48. BR Chaitman Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions Circulation 113 2006 2462 2472
49. PH Stone, NA Gratsiansky, A Blokhin, IZ Huang, L Meng the ERICA Investigators Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial J Am Coll Cardiol 48 2006 566 575
50. BR Chaitman, SL Skettino, JO Parker et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina J Am Coll Cardiol 43 2004 1375 1382
51. BR Chaitman, CJ Pepine, JO Parker the Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial JAMA 291 2004 309 316
52. JM Detry, P Sellier, S Pennaforte, D Cokkinos, H Dargie, P Mathes the Trimetazidine European Multicenter Study Group Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina Br J Clin Pharmacol 37 1994 279 288
53. H Szwed, Z Sadowski, W Elikowski et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand Eur Heart J 22 2001 2267 2274
54. M Marzilli, WW Klein Efficacy and tolerability of trimetazidine in stable angina: a meta-analysis of randomized, double-blind, controlled trials Coron Artery Dis 14 2003 171 179
55. LJ Lyon, S Fisch, MA Nevins, S Henry Perhexilene maleate in treatment of angina pectoris Lancet 297 1971 1272 1274
56. CJ Burns-Cox, KP Chandrasekhar, H Ikram et al. Clinical evaluation of perhexiline maleate in patients with angina pectoris BMJ 4 1971 586 588
57. JH Horgan, WG O'Callaghan, KK Teo Therapy of angina pectoris with low-dose perhexiline J Cardiovasc Pharmacol 3 1981 566 572
58. HD White, JB Lowe Antianginal efficacy of perhexiline maleate in patients refractory to beta-adrenoreceptor blockade Int J Cardiol 3 1983 145 155
59. PL Cole, AD Beamer, N McGowan et al. Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent Circulation 81 1990 1260 1270
60. SV Arnold, DA Morrow, K Wang the MERLIN-TIMI 36 Investigators Effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes: results from the MERLIN-TIMI 36 randomized trial Circ Cardiovasc Qual Outcomes 1 2008 107 115
61. MJ Koren, MR Crager, M Sweeney Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE) J Am Coll Cardiol 49 2007 1027 1034
62. M Kosiborod, SV Arnold, JA Spertus et al. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina) J Am Coll Cardiol 61 2013 2038 2045
63. KK Teo, JG Kelly, JF Darby, JT Ennis, JH Horgan Perhexiline during exercise training in coronary heart disease Clin Pharmacol Ther 34 1983 744 748
64. UE Ekelund, RW Harrison, O Shokek et al. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure Circ Res 85 1999 437 445
65. J George, E Carr, J Davies, JJF Belch, A Struthers High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid Circulation 114 2006 2508 2516
66. V Dzerve the MILSS I Study Group A dose-dependent improvement in exercise tolerance in patients with stable angina treated with mildronate: a clinical trial "MILSS I" Medicina (Kaunas) 47 2011 544 551
67. GA Lamas, C Goertz, R Boineau the TACT Investigators Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial JAMA 309 2013 1241 1250
68. E Escolar, GA Lamas, DB Mark et al. The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT) Circ Cardiovasc Qual Outcomes 7 2014 15 24
69. TJ Povsic, S Broderick, KJ Anstrom et al. Predictors of long-term clinical endpoints in patients with refractory angina J Am Heart Assoc 4 2015 e001287
70. KS Oh, BK Oh, CH Park et al. Cardiovascular effects of a novel selective Rho kinase inhibitor, 2-(1H-indazole-5-yl)amino-4-methoxy-6-piperazino triazine (DW1865) Eur J Pharmacol 702 2013 218 226
71. H Shimokawa, K Hiramori, H Iinuma et al. Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study J Cardiovasc Pharmacol 40 2002 751 761
72. RM Vicari, B Chaitman, D Keefe the Fasudil Study Group Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial J Am Coll Cardiol 46 2005 1803 1811
73. S Attanasio, G Schaer Therapeutic angiogenesis for the management of refractory angina: current concepts Cardiovasc Ther 29 2011 e1 11
74. M Simons, RO Bonow, NA Chronos et al. Clinical trials in coronary angiogenesis: issues, problems, consensus: An expert panel summary Circulation 102 2000 E73 E86
75. TD Henry Therapeutic angiogenesis BMJ 318 1999 1536 1539
76. TD Henry, BH Annex, GR McKendall the VIVA Investigators The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis Circulation 107 2003 1359 1365
77. M Simons, BH Annex, RJ Laham et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial Circulation 105 2002 788 793
78. CL Grines, MW Watkins, G Helmer et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris Circulation 105 2002 1291 1297
79. CL Grines, MW Watkins, JJ Mahmarian the Angiogene GENe Therapy (AGENT-2) Study Group A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina J Am Coll Cardiol 42 2003 1339 1347
80. TD Henry, CL Grines, MW Watkins et al. Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials J Am Coll Cardiol 50 2007 1038 1046
81. DW Losordo, PR Vale, RC Hendel et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia Circulation 105 2002 2012 2018
82. J Kastrup, E Jørgensen, A Rück the Euroinject One Group Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial J Am Coll Cardiol 45 2005 982 988
83. DW Losordo, TD Henry, C Davidson the ACT34-CMI Investigators Intramyocardial, autologous CD34+ cell therapy for refractory angina Circ Res 109 2011 428 436
84. N Li, YJ Yang, Q Zhang, C Jin, H Wang, HY Qian Stem cell therapy is a promising tool for refractory angina: a meta-analysis of randomized controlled trials Can J Cardiol 29 2013 908 914
85. AB Mathiasen, M Haack-Sørensen, E Jørgensen, J Kastrup Autotransplantation of mesenchymal stromal cells from bone-marrow to heart in patients with severe stable coronary artery disease and refractory angina - final 3-year follow-up Int J Cardiol 170 2013 246 251
86. TJ Povsic, C Junge, A Nada et al. A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous cd34+ cell administration in patients with refractory angina: design of the RENEW study Am Heart J 165 2013 854 861